Evommune Collaborated with Maruho to Develop and Commercialize EVO756 in Japan
- Evommune is eligible to receive ~$60M in up front & milestones along with royalties on future sales of EVO756 in Japan
- Based on P-IIa results of EVO101 in AD, Evommune discontinue the development of this program & will focus its resources on rapidly advancing its broad pipeline of systemically administered product candidates
- EVO756, a potent, highly selective small molecule antagonist of MRGPRX2 for multiple inflammatory conditions & a first-in-class oral treatment for various mast cell-mediated diseases, as well as diseases involving sensory neuron-mediated cutaneous itch. The company is expected to submit an IND Application for EVO756 to the US FDA in Q4’23 & plans to initiate clinical programs for various diseases in early 2024
Ref: PR Newswire | Image: Maruho
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.